HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
IRIX
IRIDEX Corporation
There isn't enough reported data to score IRIX yet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
IRIX Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Under pressure | |
| Under pressure | |
| Unavailable |
IRIX's revenue is currently stable, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
IRIX PE Valuation
IRIX has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
IRIX Forward outlook
There aren't enough analyst estimates for IRIX to show an outlook.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
IRIX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$0.20 | +$0.13 |
| Q1 2026 | -$0.19 | +$0.24 |
| Q4 2025 | -$0.26 | +$0.28 |
| Q3 2025 | -$0.30 | +$0.37 |
| Q2 2025 | -$0.33 | +$0.33 |
| Q1 2025 | -$0.43 | +$0.24 |
| Q4 2024 | -$0.54 | +$0.05 |
| Q3 2024 | -$0.67 | -$0.19 |
IRIX has the edge over HIMS on earnings, with more consistent year-over-year improvement.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over IRIX on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over IRIX on profitability, with a higher operating margin.
IRIX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $12.6M | -7.4% |
| Q1 2026 | $11.8M | -0.8% |
| Q4 2025 | $14.7M | +16% |
| Q3 2025 | $12.5M | +7.8% |
| Q2 2025 | $13.6M | +7.4% |
| Q1 2025 | $11.9M | +1.1% |
| Q4 2024 | $12.7M | +1.9% |
| Q3 2024 | $11.6M | -9.9% |
IRIX's revenue fell from its 2022 peak and has held roughly level since: $13M last quarter, down 7.4% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -8.2% | -1.3 points |
| Q1 2026 | -2.8% | -1 points |
| Q4 2025 | -0.1% | +3.9 points |
| Q3 2025 | -11% | +4.8 points |
| Q2 2025 | -6.9% | +14 points |
| Q1 2025 | -1.7% | +26 points |
| Q4 2024 | -4% | +21 points |
| Q3 2024 | -16% | -3 points |
IRIX's operating margin was −8.2% last quarter, down 1.3 points from the same quarter a year ago.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over IRIX on cash generation, producing positive trailing cash flow while its opponent burns cash.
IRIX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $124K | +$534K |
| Q1 2026 | -$1.4M | -$276K |
| Q4 2025 | $483K | +$1.7M |
| Q3 2025 | -$1.2M | +$1.9M |
| Q2 2025 | -$410K | +$916K |
| Q1 2025 | -$1.2M | +$491K |
| Q4 2024 | -$1.2M | -$300K |
| Q3 2024 | -$3.1M | -$1.2M |
IRIX has burned cash in almost every quarter: −$2M over the past year, against −$6M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over IRIX on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
IRIX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.6% | +107K shares |
| 1 year | +3.7% | +625K shares |
| 3 years | +8.6% | +1.4M shares |
| 5 years | +6.8% | +1.1M shares |
| Available history | +27% | +3.6M shares |
IRIX has 17M diluted shares, up 3.7% from a year ago.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
IRIX Net Leverage
IRIX's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
IRIX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 41.1 | Neutral |
| Stochastic | 20.8 | Neutral |
IRIX's weekly RSI is 41 (neutral) and its Stochastic is 21 (neutral).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
IRIX PE vs Healthcare Sector
IRIX has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
IRIX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.72 | 1.4% below |
| 20 week MA | $0.79 | 10% below |
| 50 week MA | $1.02 | 30% below |
| 100 week MA | $1.11 | 36% below |
| 200 week MA | $1.68 | 58% below |
IRIX is in a downtrend: it's below all five of its weekly moving averages, and 58% below its 200-week average.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
IRIX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $2.35 | $1.94 | -17% |
| 2021 | $1.94 | $6.22 | +221% |
| 2022 | $6.22 | $2.11 | -66% |
| 2023 | $2.11 | $2.81 | +33% |
| 2024 | $2.81 | $1.67 | -41% |
| 2025 | $1.67 | $1.23 | -26% |
| 2026 YTD | $1.23 | $0.71 | -42% |
IRIX has the edge over HIMS on returns for 2026, with the stronger performance.